Results 1 to 10 of about 59,270 (239)

Polymyxin B adjuvants against polymyxin B- and carbapenem-resistant Gram-negative bacteria. [PDF]

Future Microbiol
Aim: Polymyxin B (PMB) is one of the few therapeutic options for treating infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB). However, the emergence of PMB-resistant CR-GNB strains has prompted the exploration of antibiotic adjuvants as potential therapeutic avenues.
Salvaterra Pasquini JP, Queiroz PA, Rodrigues do Amaral PH, da Silva TC, Souza Bonfim Mendonça P, Vandresen F, Carvalho Ceolis JP, de Lima Scodro RB, Caleffi-Ferracioli KR, Cardoso RF, Dias Siqueira VL.   +10 more
europepmc   +3 more sources

Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case–control study

Annals of Intensive Care, 2022
Background The mortality of extensively drug-resistant Gram-negative (XDR GN) bacilli-induced ventilator-associated pneumonia (VAP) is extremely high. The purpose of this study was to compare the efficacy and safety of inhaled (IH) plus intravenous (IV ...
Jiao Liu, Min Shao, Qianghong Xu, Fen Liu, Xiaojun Pan, Jianfeng Wu, Lihong Xiong, Yueming Wu, Mi Tian, Jianying Yao, Sisi Huang, Lidi Zhang, Yizhu Chen, Sheng Zhang, Zhenliang Wen, Hangxiang Du, TaoWang, Yongan Liu, Wenzhe Li, Yan Xu, Jean-louis Teboul, Dechang Chen   +21 more
doaj   +1 more source

Polymyxin B Nephrotoxicity: From Organ to Cell Damage. [PDF]

PLoS ONE, 2016
Polymyxins have a long history of dose-limiting toxicity, but the underlying mechanism of polymyxin B-induced nephrotoxicity is unclear. This study investigated the link between the nephrotoxic effects of polymyxin B on renal metabolic functions and ...
Maria de Fátima Fernandes Vattimo, Mirian Watanabe, Cassiane Dezoti da Fonseca, Luciana Barros de Moura Neiva, Edson Andrade Pessoa, Fernanda Teixeira Borges   +5 more
doaj   +1 more source

Comparative Proteomics of Outer Membrane Vesicles from Polymyxin-Susceptible and Extremely Drug-Resistant Klebsiella pneumoniae

mSphere, 2023
Outer membrane vesicles (OMVs) secreted by Gram-negative bacteria serve as transporters for the delivery of cargo such as virulence and antibiotic resistance factors.
Maytham Hussein, Raad Jasim, Hakan Gocol, Mark Baker, Varsha J. Thombare, James Ziogas, Aayush Purohit, Gauri G. Rao, Jian Li, Tony Velkov   +9 more
doaj   +1 more source

Polymyxin B-Induced Skin Hyperpigmentation [PDF]

Case Reports in Medicine, 2020
Polymyxin B-induced skin hyperpigmentation is a rare adverse drug reaction (ADR). In this report, we present the case of a patient who underwent an abscess resection with right epididymitis, in which a multidrug-resistant Klebsiella pneumoniae infection (KPI) is formed.
Xueke Wen, Chunliu Luo, Weitao Lyu
openaire   +5 more sources

Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections

BMC Infectious Diseases, 2021
Objective To investigate how to use polymyxin B rationally in order to produce the best efficacy and safety in patients with carbapenem-resistant gram-negative organisms (CRO) infection. Methods The clinical characteristics and microbiological results of
G. L. Xia, R. L. Jiang
doaj   +1 more source

SpxA1 and SpxA2 act coordinately to fine-tune stress responses and virulence in Streptococcus pyogenes [PDF]

, 2017
SpxA is a unique transcriptional regulator highly conserved among members of the phylum Firmicutes that binds RNA polymerase and can act as an antiactivator. Why some Firmicutes members have two highly similar SpxA paralogs is not understood.
Gary C. Port, Larry S. McDaniel, Michael G. Caparon, Paul R. Tumminello, Zachary T. Cusumano   +4 more
core   +11 more sources

Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy

Scientific Reports, 2021
The emergence of polymyxin resistance in Gram-negative bacteria infections has motivated the use of combination therapy. This study determined the mutant selection window (MSW) of polymyxin B alone and in combination with meropenem and fosfomycin against
Nayara Helisandra Fedrigo, Danielle Rosani Shinohara, Josmar Mazucheli, Sheila Alexandra Belini Nishiyama, Floristher Elaine Carrara-Marroni, Frederico Severino Martins, Peijuan Zhu, Mingming Yu, Sherwin Kenneth B. Sy, Maria Cristina Bronharo Tognim   +9 more
doaj   +1 more source

Inappropriate Doses of Intravenous Polymyxin B after Renal Adjustment Lead to Treatment Failure

Brazilian Journal of Pharmaceutical Sciences, 2021
Sub-therapeutic doses, shorter duration of therapy, female gender, bacteremia, and renal impairment were among independent predictors of polymyxin B treatment failure.
Bahiah Ismail, Mohd Nazri Shafei, Azian Harun, Saedah Ali, Mahamarowi Omar, Zakuan Zainy Deris   +5 more
doaj   +1 more source

Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance

Frontiers in Pharmacology, 2022
Background: Polymyxin B has become the last choice for patient with carbapenem-resistant bacterial infection. However, the optimal dosing of polymyxin B in critically ill children receiving continuous renal replacement therapy (CRRT) remains unclear.Case
Caifang Xu, Xiaofen Liu, Xiaofen Liu, Yun Cui, Xiaolan Huang, Xiaolan Huang, Yu Wang, Yu Wang, Yaxin Fan, Yaxin Fan, Hailan Wu, Hailan Wu, Xin Li, Xin Li, Beining Guo, Beining Guo, Jing Zhang, Jing Zhang, Jing Zhang, Yucai Zhang   +19 more
doaj   +1 more source